Dynamics of Epstein-Barr virus DNA levels in serum during EBV-associated disease

✍ Scribed by Christoph Berger; Philip Day; Gabriela Meier; Walter Zingg; Walter Bossart; David Nadal

• Publisher: John Wiley and Sons
• Year: 2001
• Tongue: English
• Weight: 222 KB
• Volume: 64
• Category: Article
• ISSN: 0146-6615
• DOI: 10.1002/jmv.1078

✦ Synopsis

Abstract

A real‐time polymerase chain reaction assay for quantitation of Epstein‐Barr virus (EBV) DNA in serum was developed. This assay detected EBV DNA in 24 (89%) of 27 sera from patients with infectious mononucleosis, but only in 9 (18%) of 51 sera from EBV carriers (P < 0.001) and in none of the sera from 32 EBV‐seronegative individuals. EBV DNA levels were higher in sera from infectious mononucleosis (median 8,000, range 1833–150,069 copies/ml) than from carriers (median < 2, range < 2–2980; P < 0.001). In sera of 36 children with infectious mononucleosis followed prospectively, EBV DNA levels correlated inversely with the duration of symptoms. Among 18 children with tumors including Hodgkin's disease (n = 7), non‐Hodgkin's lymphoma (n = 6), Burkitt's lymphoma (n = 1), lymphoproliferative disorder (n = 4), and osteosarcoma (n = 1), EBV DNA was detected in serum from those 9 (100%) expressing EBV in the tumor (Hodgkin's disease, 3; non‐Hodgkin's lymphoma, 2; lymphoproliferative disorder, 4), the levels peaking at diagnosis and correlating with disease activity. Quantitation of EBV DNA in serum may offer a simple means of monitoring patients at risk of EBV‐associated lymphoproliferation. J. Med. Virol. 64:505–512, 2001. © 2001 Wiley‐Liss, Inc.